The Medicines Patent Pool operates according to its transparency policy. The Policy states that following each meeting of the Governance Board, a report of the decisions will be made available to the public.
- Governance Board Resolution on expanding MPP’s remit into the licensing of technology transfer with an initial focus on COVID-19 vaccines and pandemic preparedness: 19 May 2021
- Governance Board Meeting: 13 April 2021 (held virtually due to COVID-19)
- Governance Board Meeting: 13 October 2020 (hybrid meeting due to COVID-19)
- Extraordinary Governance Board Meeting: 27 May 2020 (held virtually due to COVID-19)
- Governance Board Meeting: 28 April 2020 (held virtually due to COVID-19)
- Governance Board Resolution on temporarily expanding MPP’s remit to include any health technology that could contribute to the global response to COVID-19: 31 March 2020
- Governance Board Meeting: 14-15 October 2019
- Governance Board Meeting: 8-9 April 2019
- Governance Board Meeting: 22-23 October 2018
- Governance Board Meeting: 26-27 March 2018
- Governance Board Meeting: 19-20 September 2017
- Governance Board Meeting: 10-11 April 2017
- Governance Board Meeting: 19-5 December 2016
- Governance Board Decision taken by correspondence: 14 November 2016
- Governance Board Decision taken by correspondence: 8 November 2016
- Governance Board Resolution on Establishing a Comprehensive Framework of Conflict of Interest and Compliance Policies: 31 October 2016
- Governance Board Meeting: 29 August 2016
- Governance Board Meeting: 19-20 May 2016
- Governance Board Meeting: 25 October 2015
- Governance Board Teleconference: 15 September 2015
- Governance Board Meeting: 15-24 April 2015
- Governance Board Meeting: 14-19 September 2014
- Chariman’s Summary about ViiV’s dolutegravir licensing agreement for upper-middle-income countries: November 2020
- Chairman’s Summary about Pfizer’s sutezolid licensing agreement: 23 October 2019
- Chairman’s Summary about Gilead’s BIC licensing agreement: 29 August 2017
- Chairman’s Summary about Pharco’s ravidasvir licensing agreement: 11-12 April 2017
- Chairman’s Summary about the Johns Hopkins University’s sutezolid licensing agreement: 9 November 2016
- Chairman’s Summary about AbbVie’s LPV/r: 11 December 2015
- Chairman’s Summary about the University of Liverpool’s Solid Drug Nanoparticle (SDN) technology: 1 December 2015
- Chairman’s Summary about Bristol-Myers Squibb’s DCV licensing agreement: 18 November 2015
- Chairman’s Summary about MSD’s paediatric RAL licensing agreement: 19 February 2015
- Chairman’s Summary about AbbVie’s paediatric LPV/r licensing agreement: 21 November 2014
- Chairman’s Summary about Gilead’s proposed amendements to the agreement to incorporate TAF: 22 July 2014
- Chairman’s Summary about ViiV Healthcare’s DTG licensing agreement: 30 March 2014
- Chairman’s Summary about BMS’s ATZ licensing agreement: 3 December 2013
- Chairman’s Summary about Roche’s valganciclovir agreement: 22 July 2013
- Chairman’s Summary about ViiV Healthcare’s ABC licensing agreement and Memorandum of Understanding: 11 February 2013
- Chairman’s Summary about MPP’s consultative mechanisms: 8 December 2011